Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Opdualag

(op-DOO-uh-lag)
A combination of nivolumab and relatlimab used to treat adults and children aged 12 years or older with melanoma that has spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Opdualag binds to the proteins PD-1 and LAG-3, which are found on T cells (a type of immune cell). Blocking these proteins may help the immune system kill cancer cells. The combination of nivolumab and relatlimab may work better than either drug alone. Opdualag is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called nivolumab and relatlimab.
More Information
Search NCI's Dictionary of Cancer Terms